Gilde Healthcare and Norwest co-led round to commercialize the Hēlo

Gilde Healthcare和Norwest共同领投了Hēlo的商业化轮融资。

®

®

Thrombectomy Platform

血栓切除平台

MENLO PARK, Calif.

门洛帕克，加利福尼亚州

,

，

April 7, 2026

2026年4月7日

/PRNewswire/ -- Endovascular Engineering, Inc. ('E2'), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE), today announced an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, as well as the two existing undisclosed strategic investors and a new global strategic investor..

/PRNewswire/ -- Endovascular Engineering, Inc.（简称“E2”），一家专注于推进静脉血栓栓塞症（VTE）治疗的商业阶段医疗技术公司，今天宣布完成了超额认购的8000万美元C轮融资，由Gilde Healthcare和Norwest共同领投，现有投资者包括Santé Ventures、415 Capital、S3 Ventures、Panakès Partners、M&L Healthcare Investments，以及两家未披露的战略投资者和一位新的全球战略投资者参与。

The new financing supports commercialization of E2's novel Hēlo

新融资支持了E2新型Hēlo的商业化。

®

®

Thrombectomy Platform for the treatment of pulmonary embolism, the third leading cause of cardiovascular death.

用于治疗肺栓塞的血栓切除平台，肺栓塞是心血管疾病死亡的第三大原因。

The Hēlo

赫洛

®

®

Platform was designed to address the limitations of legacy systems and features a patented dual-action mechanism that integrates aspiration with mechanical clot disruption. The system delivers large-bore performance through a small-profile catheter, enabling efficient single-pass procedures. E2's integrated platform is designed to support procedural efficiency and clinical performance as adoption of mechanical thrombectomy continues to expand..

该平台旨在解决传统系统的局限性，采用了一种获得专利的双作用机制，将抽吸与机械血栓破坏相结合。系统通过小口径导管提供大口径性能，实现高效的单次通过操作。随着机械血栓切除术的应用不断扩大，E2的集成平台旨在支持手术效率和临床表现。

'This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE space,' said Dan Rose, chief executive officer at E2. 'We are incredibly proud of the capabilities of the Hēlo

“这是E2的一个关键里程碑，因为我们继续在VTE领域为患者和医生改善选择的使命，”E2首席执行官丹·罗斯表示。“我们为Hēlo的能力感到无比自豪。

®

®

Platform, and this financing enables us to build a strong commercial organization while continuing important investments in R&D and Operations.'

这一融资使我们能够在继续对研发和运营进行重要投资的同时，建立一个强大的商业组织。

This investment marks Gilde's return to the VTE category, having previously led Inari Medical's Series C commercial financing and remained a key investor until its successful acquisition by Stryker. This reflects strong conviction in E2's differentiated approach and the potential of the Hēlo

这项投资标志着Gilde回归VTE领域，此前曾主导Inari Medical的C轮融资并一直是其关键投资者，直到被Stryker成功收购。这反映了对E2差异化方法及Hēlo潜力的高度认可。

®

®

platform to shape the next generation of thrombectomy technology.

平台，旨在塑造下一代血栓切除技术。

'E2 represents the type of innovation we look for - technology that meaningfully advances clinical care and has the potential to define a category,' said Geoff Pardo, general partner at Gilde Healthcare. 'We believe the Hēlo

“E2 代表了我们所寻找的创新类型——能够显著推进临床护理的技术，并有潜力定义一个类别，”Gilde Healthcare 的普通合伙人 Geoff Pardo 表示。“我们相信 Hēlo…”

®

®

Platform addresses unmet needs in thrombectomy and are excited to support E2 as they scale toward commercialization and broader clinical impact.'

该平台解决了血栓切除术中未满足的需求，并且很高兴支持E2，因为他们正朝着商业化和更广泛的临床影响迈进。

'Pulmonary embolism is a complex and often life-threatening condition, and there remains a need for more effective procedural solutions,' said Zack Scott, M.D., general partner at Norwest. 'We are impressed by E2's leadership team and their thoughtful approach to building a scalable commercial organization.

“肺栓塞是一种复杂且常常危及生命的疾病，仍然需要更有效的手术解决方案，”Norwest的普通合伙人扎克·斯科特（Zack Scott）博士说道。“E2的领导团队以及他们建立可扩展的商业组织的周到方法给我们留下了深刻印象。”

E2's technology will become the platform of choice for treating pulmonary embolism with mechanical thrombectomy, and we look forward to supporting their next phase of growth.'.

E2的技术将成为治疗肺栓塞的机械血栓切除术的首选平台，我们期待着支持他们的下一个增长阶段。

Both Scott and Pardo will join the E2 Board.

斯科特和帕尔多都将加入E2董事会。

About Endovascular Engineering, Inc.

关于血管内工程公司

Endovascular Engineering, Inc. ('E2'), is commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE). The company is developing and deploying solutions designed to improve clinical outcomes and procedural efficiency in clot removal, aimed at addressing the complex challenges in VTE intervention.

血管内工程公司（“E2”）是一家处于商业化阶段的医疗技术公司，专注于推进静脉血栓栓塞症（VTE）的治疗。该公司正在开发和部署旨在改善血栓清除临床结果和操作效率的解决方案，以应对VTE干预中的复杂挑战。

E2 is backed by leading investors including Norwest, Gilde Healthcare, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments..

E2 得到了包括 Norwest、Gilde Healthcare、Santé Ventures、415 Capital、S3 Ventures、Panakès Partners 和 M&L Healthcare Investments 在内的领先投资者的支持。

Hēlo

你好

®

®

Thrombectomy System - Indications for Use

血栓切除系统 - 使用指征

The Hēlo

赫洛

®

®

Thrombectomy System is indicated for: The non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature. The system allows for injection, infusion, and/or aspiration of contrast media and other fluids into or from blood vessels. The Hēlo

血栓切除系统适用于：从肺动脉和静脉血管中非手术去除栓子和血栓。该系统可以用于向血管内注射、灌注和/或抽吸造影剂和其他液体。Hēlo

®

®

Thrombectomy System is intended for use in the peripheral veins and for the treatment of pulmonary embolism.

血栓切除系统旨在用于外周静脉和治疗肺栓塞。

Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use.

注意：美国联邦法律限制这些设备仅能由医生或根据医生的指示销售。使用前，请参阅使用说明书以获取完整的产品适应症、禁忌症、警告、注意事项、潜在不良事件和详细的使用说明。

For more information, please visit

更多信息，请访问

www.e2helo.com

www.e2helo.com

and follow us on LinkedIn @E2-EndovascularEngineering.

请在LinkedIn上关注我们 @E2-EndovascularEngineering。

SOURCE E2

来源 E2

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示